Skip to main content
. Author manuscript; available in PMC: 2014 Aug 14.
Published in final edited form as: Support Care Cancer. 2008 Nov 13;17(5):563–572. doi: 10.1007/s00520-008-0528-8

Table 3.

Severity of acute and delayed nausea and vomiting

Severitya Mean±SD P valueb
(apripetant=no)
P valueb
(apripetant=yes)

Placebo group
(n=46)
Ginger 1.0 g group
(n=43)
Ginger 2.0 g group
(n=40)
Nausea
 Acute
  No apripetant 2.8±1.3 (n=23) 3.1±1.2 (n=21) 3.0±1.1 (n=20) 0.47 0.55
  Yes apripetant 3.1±1.5 (n=8) 2.8±1.1 (n=12) 2.8±1.5 (n=10)
 Delayed
  No apripetant 3.0±1.3 (n=23) 3.0±1.1 (n=25) 3.2±1.1 (n=17) 0.69 0.01
  Yes apripetant 2.2±0.7 (n=9) 2.9±1.3 (n=11) 3.9±0.9 (n=9)
Vomiting
 Acute
  No apripetant 3.6±1.4 (n=11) 3.1±1.4 (n=14) 2.9±0.9 (n=11) 0.61 0.91
  Yes apripetant 4.0±1.7 (n=3) 3.4±0.6 (n=5) 3.7±1.5 (n=6)
 Delayed
  No apripetant 4.0±1.3 (n=7) 2.7±0.9 (n=12) 3.7±1.0 (n=7) 0.88 0.77
  Yes apripetant 3.0±0.0 (n=1) 3.0±1.4 (n=5) 3.6±1.3 (n=5)
a

Severity of nausea and vomiting graded on a six-point Likert scale graded as 1=very mild, 2=mild, 3=moderate, 4=severe, 5=very severe, and 6=intolerable

b

P values were calculated using Cochran Mantel–Haenszel tests stratified by apripetant (yes or no)